Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study) (LUNGEVITY)

GFPC Investigation

Status: Enrolling

Conditions: Metastatic Small Cell Lung Cancer; Metastatic NSCLC; Metastatic Lung Cancer

Treatments: Behavioral: Questionnaire Aix-Marseille-Université (AMU); Behavioral: Hospital Anxiety and Depression scale (HAD); Behavioral: Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13)

Study type: Observational

Funder types: Other

Identifiers

NCT07243132

GFPC INVESTIGATION 07-2019

Details and patient eligibility

About

The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment.

Participants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study.

They will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient over 18 years old
• Patients alive after more than three years from diagnosis with stage IV or Stage III NSCLC or SCLC, not treated with cytotoxic chemotherapy at the time of inclusion (the patient may be undergoing imunotherapy, targeted therapy or surveillance).
• Patients covered by the French National Health Insurance program or with thirdparty-payer health insurance

Exclusion criteria

• Difficulties for understanding French
• Patients undergoing treatment with cytotoxic chemotherapy
• Patients under legal guardianship, under curatorship or tutorship
• Insufficient cognitive capacity to answer questions
• Inability to obtain data collection (lost to follow-up, patient's refusal for data collection)
• Patients refusing the collection of their data (an information sheet will be provided)

Trial design

1,000 participants in 1 patient group

Long-Terms Responders in metastatic Lung Cancer

Description:

Long-term responders defined as patients alive for three years after diagnosis of metastatic Lung cancer (NSCLC and SCLC) and not receiving cytotoxic chemotherapy at the time of inclusion.

Treatment:

Behavioral: Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13)

Behavioral: Hospital Anxiety and Depression scale (HAD)

Behavioral: Questionnaire Aix-Marseille-Université (AMU)